Systemic blockage of nitric oxide synthase by L-NAME increases left ventricular systolic pressure, which is not augmented further by Intralipid®.
Intravenous lipid emulsions (LEs) are effective in the treatment of toxicity associated with various drugs such as local anesthetics and other lipid soluble agents. The goals of this study were to examine the effect of LE on left ventricular hemodynamic variables and systemic blood pressure in an in vivo rat model, and to determine the associated cellular mechanism with a particular focus on nitric oxide. Two LEs (Intralipid(®) 20% and Lipofundin(®) MCT/LCT 20%) or normal saline were administered intravenously in an in vivo rat model following induction of anesthesia by intramuscular injection of tiletamine/zolazepam and xylazine. Left ventricular systolic pressure (LVSP), blood pressure, heart rate, maximum rate of intraventricular pressure increase, and maximum rate of intraventricular pressure decrease were measured before and after intravenous administration of various doses of LEs or normal saline to an in vivo rat with or without pretreatment with the non-specific nitric oxide synthase inhibitor N(ω)-nitro-L-arginine-methyl ester (L-NAME). Administration of Intralipid(®) (3 and 10 ml/kg) increased LVSP and decreased heart rate. Pretreatment with L-NAME (10 mg/kg) increased LSVP and decreased heart rate, whereas subsequent treatment with Intralipid(®) did not significantly alter LVSP. Intralipid(®) (10 ml/kg) increased mean blood pressure and decreased heart rate. The increase in LVSP induced by Lipofundin(®) MCT/LCT was greater than that induced by Intralipid(®). Intralipid(®) (1%) did not significantly alter nitric oxide donor sodium nitroprusside-induced relaxation in endothelium-denuded rat aorta. Taken together, systemic blockage of nitric oxide synthase by L-NAME increases LVSP, which is not augmented further by intralipid(®).
1. Department of Anesthesiology and Pain Medicine, Gyeongsang National University Hospital, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea;
Il-Woo
IW
Shin
2. Clinical Research Institute, Gyeongsang National University Hospital, Jinju, Korea;
Young-Sool
YS
Hah
3. Department of Anesthesiology and Pain Medicine, Gyeongsang National University School of Medicine, Jinju, Korea;
Cheol
C
Kim
4. Department of Anesthesiology and Pain Medicine, Gyeongsang National University Hospital, Jinju, Korea;
Jungchul
J
Park
5. Department of Biological Sciences, California State University, Long Beach, California, USA;
Heewon
H
Shin
4. Department of Anesthesiology and Pain Medicine, Gyeongsang National University Hospital, Jinju, Korea;
Kyeong-Eon
KE
Park
1. Department of Anesthesiology and Pain Medicine, Gyeongsang National University Hospital, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea;
Seong-Ho
SH
Ok
1. Department of Anesthesiology and Pain Medicine, Gyeongsang National University Hospital, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea;
Heon-Keun
HK
Lee
1. Department of Anesthesiology and Pain Medicine, Gyeongsang National University Hospital, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea;
Young-Kyun
YK
Chung
6. Department of Anesthesiology and Pain Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea;
Haeng Seon
HS
Shim
7. Department of Information Statistics and RINS, Gyeongsang National University, Jinju, 660-701, Korea.
Dong Hoon
DH
Lim
1. Department of Anesthesiology and Pain Medicine, Gyeongsang National University Hospital, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea;
Ju-Tae
JT
Sohn
D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D004338:Drug Combinations; D004655:Emulsions / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects; D008297:Male; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D010743:Phospholipids / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013012:Sorbitol / Q000494:pharmacology; D013024:Soybean Oil / Q000494:pharmacology*; D013992:Tiletamine / Q000494:pharmacology; D014991:Xylazine / Q000494:pharmacology; D015041:Zolazepam / Q000494:pharmacology
D004338:Drug Combinations; D004655:Emulsions; D010743:Phospholipids; C545823:soybean oil, phospholipid emulsion; C006131:tiletamine, zolazepam drug combination; C008288:Lipofundin; C026512:arginine methyl ester; D014991:Xylazine; D013992:Tiletamine; D009569:Nitric Oxide; D013012:Sorbitol; D013024:Soybean Oil; D001120:Arginine; D019001:Nitric Oxide Synthase; D015041:Zolazepam
L-NAME.; blood pressure; left ventricular systolic pressure; lipid emulsion; nitric oxide